source
- Roche signs $2.5 billion deal with Hanmi for experimental obesity drug targeting muscle lossRoche's Genentech unit has agreed to acquire global rights (outside South Korea) to Hanmi's clinical-stage urocortin-2 analog, HM17321, as part of a deal valued up to $2.5 billion. The agreement i…
- TwinStrand wins patent lawsuit as GSK’s hepatitis B therapy receives Japanese approvalTwinStrand Biosciences, a DNA sequencing spin‑out from the University of Washington, announced it has prevailed in a patent infringement lawsuit against a California‑based competitor. The court’s…